Emerging Drugs for the Chemotherapy Induced Peripheral Neuropathy Treatment Will Soon Benefit Patients: A Focus on Recent Clinical Trials

Los Angeles, USA , May 19, 2021 (GLOBE NEWSWIRE) — Emerging Drugs for the Chemotherapy Induced Peripheral Neuropathy Treatment Will Soon Benefit Patients: A Focus on Recent Clinical Trials 

Chemotherapy-Induced Peripheral Neuropathy Pipeline Report covers a complete clinical trials analysis of 15+ drugs and 15+ companies, which are developing therapies to change the treatment outlook.

DelveInsight’s “Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Insight” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Chemotherapy-Induced Peripheral Neuropathy pipeline landscapes. It comprises CIPN pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chemotherapy Induced Peripheral Neuropathy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive CIPN pipeline products.     

Some of the key takeaways of the Chemotherapy Induced Peripheral Neuropathy Pipeline Report  

• Prominent companies such as MakScientific, Regenacy Pharmaceuticals, Apexian Pharmaceuticals, Metys Pharmaceuticals AG, MediciNova, Egetis Therapeutics, WEX Pharmaceuticals, Sonnet BioTherapeutics, Toray Industries, EA Pharma, AnnJi Pharmaceutical, Asahi Kasei Pharma, Achelios Therapeutics, PeriphaGen, KannaLife Sciences, Osmol Therapeutics, Winsantor,  YD Life Science, Solasia Pharma, Enveric Biosciences, AxoProtego Therapeutics, and others are developing potential drug candidates to boost the Chemotherapy Induced Peripheral Neuropathy treatment scenario. 
• Out of the emerging therapies, Tetrodotoxin (WEX Pharmaceuticals) is in Phase III of clinical development while Ibudilast (MediciNova) is in Phase II development phase. MN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule macrophage migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors.
• Chemotherapy-Induced Peripheral Neuropathy pipeline therapies in the early stage of development include APX 3330 (Apexian Pharmaceuticals) in Phase I of clinical trials, and AM 1710 (MakScientific) is still in the preclinical phase of development.
• PledOx (calmangafodipir), developed by Egetis Therapeutics, is a “first-in-class” drug candidate designed to prevent nerve damage caused by chemotherapy without reducing its anticancer effects. The phase III program was prematurely stopped in the second quarter of 2020. In December 2020, Pledpharma announced that PledOx® did not meet the efficacy endpoint in the prematurely closed Phase 3 POLAR program. The occurrence and type of adverse events observed were generally consistent with the expected toxicity caused by the chemotherapy and the patient populations studied. Based on further evaluation of the results from the POLAR studies, the strategic next steps for PledOx will be determined together with Solasia.
• ART-123 (Asahi Kasei Pharma) is a soluble recombinant human thrombomodulin. ART-123 inhibits the coagulation process by accelerating the activation of protein C by thrombin. The drug is currently in phase 2 of clinical trials for the treatment of Chemotherapy-induced Peripheral Neuropathy. 
• Toray Industries is conducting a phase 2 study to assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TRK-750 in Colorectal Cancer Patients With Chemotherapy-induced Peripheral Neuropathy Following Oxaliplatin-containing Chemotherapy in the Adjuvant Setting. 

Get an overview of pipeline landscape @ CIPN Clinical Trials Analysis 

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common, dose-dependent adverse effect of many frequently prescribed chemotherapy and biotherapy drugs, including taxanes, platinum-based drugs, vinca alkaloids, thalidomide, bortezomib, and interferon. 

However, there are currently no approved drugs available to prevent or treat CIPN. Certain chemotherapy drugs are more likely to cause neuropathy. These include platinum drugs, such as oxaliplatin; taxanes, such as docetaxel; vinca alkaloids, such as vincristine; and myeloma treatments, such as bortezomib. Other chemotherapy drugs can also cause neuropathy. 

Chemotherapy-Induced Peripheral Neuropathy Emerging Drugs

• Pledox (Calmangafodipir): Egetis Therapeutics

PledOx (akacalmangafodipir, SP-04), being developed by Pledpharma (now Egetis Therapeutics AB), is a first in class drug candidate developed for the prevention of nerve damage caused by chemotherapy treatment in colorectal cancer patients. 

Research and Development
Phase III 
NCT03654729
Phase III (POLAR-M): In October 2018, PledPharma initiated a Phase III, multicenter, double-blind, placebo-controlled study to establish the efficacious dose of PledOx in the prevention of chronic chemotherapy-induced peripheral neuropathy (CIPN) induced by oxaliplatin. This Phase III trial enrolled 291 participants and got completed in August 2020. 

NCT04034355: Phase III (POLAR-A): In November 2018, PledPharm, in collaboration with Solasia Pharma, initiated a phase III, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent CIPN in the adjuvant treatment of patients with stage III or high-risk stage II colorectal cancer. A total of 301 participants were enrolled in this trial, and this trial was completed in August 2020.

• ART 123: Asahi Kasei Pharma

ART 123 (recombinant human thrombomodulin alpha, marketed as Recomodulin® in Japan), the company’s lead product candidate, represents a promising new treatment for severe sepsis with coagulopathy. ART-123 is a soluble recombinant human thrombomodulin. ART-123 inhibits the coagulation process by accelerating the activation of protein C by thrombin. The drug is currently in phase 2 of clinical trials for the treatment of Chemotherapy-induced Peripheral Neuropathy

Research and Development
Phase II
NCT04492436: In July 2021, Asahi Kasei Pharma will initiate a trial titled “A Randomized, Double-blind, Placebo-controlled, Multi-national, Multi-center, Parallel-group, Phase 2b Assessing ART-123’s Effect on Preventing Sensory Symptoms of OIPN in Unresectable mCRC Subjects Receiving Oxaliplatin-containing Chemo”. The aim of this study is to compare the efficacy and safety of ART-123 (low and high dose) to placebo on sensory symptoms of oxaliplatin-induced peripheral neuropathy (OIPN) in patients with unresectable metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy. The trial is expected to get completed by July 2024.

For further information, refer to the detailed report @ Chemotherapy-Induced Peripheral Neuropathy Pipeline Therapeutics 

Scope of CIPN Pipeline Drug Insight    

• Coverage: Global 
• Major Players: 15+  Key Players
• Prominent Players: MakScientific, Regenacy Pharmaceuticals, Apexian Pharmaceuticals, Metys Pharmaceuticals AG, MediciNova, Egetis Therapeutics, WEX Pharmaceuticals, Sonnet BioTherapeutics, Toray Industries, EA Pharma, AnnJi Pharmaceutical, Asahi Kasei Pharma, Achelios Therapeutics, PeriphaGen, KannaLife Sciences, Osmol Therapeutics, Winsantor,  YD Life Science, Solasia Pharma, Enveric Biosciences, AxoProtego Therapeutics, and many others.   
• Key Drugs Profiles: 15+ Products
• Phases:  

• • Chemotherapy-Induced Peripheral Neuropathy Therapies Late-stage (Phase III)  
  • CIPN Therapies Mid-stage (Phase II)
  • Chemotherapy-Induced Peripheral Neuropathy Therapies Early-stage (Phase I) 
  • CIPN Pre-clinical stage and Discovery candidates     
  • Discontinued and Inactive candidates 

• • Sodium channel antagonists
  • Toll-like receptor 4 antagonists
  • Iron chelating agents
  • DNA apurinic apyrimidinic site lyase inhibitors
  • Angiogenesis inhibitors
  • HDAC6 protein inhibitors
  • Cannabinoid receptor CB2 agonists

• • Small Molecule 
  • Gene Therapy 
  • Stem Cell Therapy 

• • Intravenous  
  • Inhalation 
  • Subcutaneous 
  • Oral 

• • Monotherapy
  • Combination
  • Mono/Combination 

Key Questions regarding Current Chemotherapy-Induced Peripheral Neuropathy Treatment Landscape and Emerging Therapies Answered in the Pipeline Report  

• What are the current options for Chemotherapy Induced Peripheral Neuropathy treatment?
• How many companies are developing therapies for the treatment of CIPN? 
• How many are Chemotherapy-Induced Peripheral Neuropathy emerging therapies in the early-stage, mid-stage, and late development stages to treat CIPN? 
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Chemotherapy Induced Peripheral Neuropathy market? 
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies for the treatment of CIPN?  
• What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Chemotherapy-Induced Peripheral Neuropathy therapies? 
• What are the critical designations that have been granted for the emerging therapies for Chemotherapy Induced Peripheral Neuropathy? 
• How many patents are granted and pending for the emerging therapies to treat CIPN?   

Table of Contents

Get a customised pipeline report @ Chemotherapy-Induced Peripheral Neuropathy Drugs Pipeline Report  

Related Reports 

DelveInsight’s CIPN – Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight’s Chemotherapy-Induced Peripheral Neuropathy (CIPN) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology. 

DelveInsight’s ‘Gene Therapy for Ocular Rare Disease -Market Insights, Competitive Landscape and Market Forecast – 2026’ report delivers an in-depth understanding of the disease. 

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects.

DelveInsight’s Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease. 

DelveInsight’ s IgA Nephropathy (IgAN) – Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight’s IgG4-Related Disease- Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed understanding of historical and forecasted epidemiology.  

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.